AbbVie Inc. vs Banco Bilbao Vizcaya Argentaria, S.A.: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Banco Bilbao Vizcaya Argentaria, S.A. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Banco Bilbao Vizcaya Argentaria, S.A., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Banco Bilbao Vizcaya Argentaria, S.A. is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against ~$41.7B for Banco Bilbao Vizcaya Argentaria, S.A., while their respective market capitalizations stand at $465.8B and $139.7B. AbbVie Inc. is headquartered in United States and Banco Bilbao Vizcaya Argentaria, S.A. in Spain, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie became an independent public biopharmaceutical company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. Humira initially dominated its portfolio. AbbVie has since added Pharmacyclics, Allergan, ImmunoGen, and Cerevel and now reports major portfolios in immunology, neuroscience, oncology, and aesthetics.

Banco Bilbao Vizcaya Argentaria, S.A.: BBVA is a Spanish banking group that earns more abroad than at home. It is Spain's second-largest bank, but Mexico produced ~$5.95B (EUR5.264B) of its ~$11.9B (EUR10.511B) net attributable profit in 2025, with Turkey, Colombia, Peru, Argentina, Uruguay and a corporate and investment banking arm making up the rest. The group employed 127,174 people at the end of 2025 and served 81.2 million active customers.

AbbVie Inc. and Banco Bilbao Vizcaya Argentaria, S.A. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Banco Bilbao Vizcaya Argentaria, S.A..

AbbVie Inc. business model: AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Its FY2025 portfolios were led by immunology at $30.406 billion, neuroscience at $10.767 billion, oncology at $6.655 billion, and aesthetics at $4.860 billion. The company funds internal research and supplements its pipeline through licensing and acquisitions.

Banco Bilbao Vizcaya Argentaria, S.A. business model: BBVA runs a universal banking model built on local subsidiaries that fund themselves with local deposits, so a shock in one country does not drain the parent. Customer deposits reached ~$568B (EUR502.5B) at the end of 2025 against ~$534B (EUR472.7B) of gross loans, and net interest income of ~$29.7B (EUR26.280B) provided about 71 percent of gross income. Fees from payments, cards, asset management and insurance added ~$9.28B (EUR8.215B) and net trading income ~$3B (EUR2.656B). Distribution is mostly digital: 81.2 million active customers were served through 5,642 branches and 31,015 ATMs, and the efficiency ratio of 38.8 percent is one of the lowest among large European banks.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Banco Bilbao Vizcaya Argentaria, S.A..

AbbVie Inc. competitive advantage: AbbVie's scale rests on its immunology portfolio, specialist commercial infrastructure, approved products across several therapeutic areas, and acquired oncology, neuroscience, and aesthetics assets. Those strengths are offset by patent-expiration, clinical-development, safety, reimbursement, and pricing risks described in its Form 10-K.

Banco Bilbao Vizcaya Argentaria, S.A. competitive advantage: BBVA's first advantage is scale in Mexico, where BBVA Mexico is the largest bank in the country and produced ~$5.95B (EUR5.264B) of net attributable profit in 2025, close to half the group total. The second is cost: operating expenses grew 1.0 percent in euros in 2025 while gross income grew 4.1 percent, holding the efficiency ratio at 38.8 percent with a branch network trimmed to 5,642 offices. Group ROTE of 19.3 percent is a level BBVA describes as leading among large European banks.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Banco Bilbao Vizcaya Argentaria, S.A. each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.

Banco Bilbao Vizcaya Argentaria, S.A. growth strategy: After the Banco Sabadell offer lapsed in October 2025, BBVA's growth plan rests on organic lending, digital expansion in Europe and capital returns. Loans and advances to customers grew 11.5 percent in 2025 and customer funds 13.5 percent. The group opened a branch-free digital bank in Italy in October 2021, which passed 800,000 customers by its fourth anniversary and targets one million during 2026, and launched a second digital bank in Germany in June 2025. Capital released by the 2021 transfer of BBVA USA to PNC still underpins buybacks and dividends, with half of 2025 profit earmarked for shareholders.

A closer look at the financial trajectory of AbbVie Inc. and Banco Bilbao Vizcaya Argentaria, S.A. rounds out the comparison.

AbbVie Inc.: AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets.

Banco Bilbao Vizcaya Argentaria, S.A.: BBVA's profit is spread across five business areas. In 2025 Spain contributed ~$4.72B (EUR4.175B) of net attributable profit, Mexico ~$5.95B (EUR5.264B), Turkey ~$910M (EUR805M), South America ~$820M (EUR726M) and Rest of Business ~$709M (EUR627M), while the Corporate Center recorded a ~$1.23B (EUR1.086B) loss. Gross income rose 4.1 percent in reported euros but 16.3 percent at constant exchange rates, the gap being mostly the weaker Mexican peso. Loan-loss impairments were ~$6.86B (EUR6.073B) with a cost of risk of 1.39 percent, and the NPL ratio improved to 2.7 percent with 85 percent coverage. CET1 capital closed at 12.70 percent against a 9.28 percent requirement, and BBVA set total 2025 shareholder distributions at 50 percent of profit, EUR0.92 per share in cash.